3,4-Methylenedioxyamphetamine

From Wikipedia, the free encyclopedia

3,4-Methylenedioxyamphetamine
Systematic (IUPAC) name
1-(benzo[1,3]dioxol-5-yl)propan-2-amine
Identifiers
CAS number  ?
4764-17-4 51497-09-7 61614-60-6 65620-66-8
ATC code  ?
PubChem 1614
Chemical data
Formula C10H13NO2 
Mol. mass 179.22 g/mol
SMILES search in eMolecules, PubChem
Pharmacokinetic data
Bioavailability  ?
Metabolism Hepatic, CYP extensively involved
Half life dose dependent 6-10 hours
Excretion Renal
Therapeutic considerations
Pregnancy cat.

?

Legal status

Prohibited (S9)(AU) Schedule III(CA) Class A(UK) Schedule I(US)

Routes Sublingual

3,4-Methylenedioxyamphetamine, or MDA, is a psychedelic hallucinogenic drug and empathogen/entactogen of the phenethylamine family. It was first synthesized by G. Mannish and W. Jacobson in 1910. There are about 20 different synthetic routes described in the literature for its preparation.

Contents

MDA was first used in animal tests in 1939, and human trials began in 1941 in the exploration of possible therapies for Parkinson's disease. From 1949 to 1957, more than 500 human subjects were given MDA in an investigation of its potential use as an antidepressant and/or anorectic by Smith, Klein, and French. The United States Army also experimented with the drug, code named EA-1298, while working to develop a truth drug or incapacitating agent. One human subject died in January 1953 after being intravenously injected with 500mg of the drug. MDA was patented as a cough suppressant by H. D. Brown in 1958, as an ataractic by Smith, Klein, and French in 1960, and as an anorectic under the trade name “Amphedoxamine” in 1961. Several researchers, including Claudio Naranjo, have explored MDA in the field of psychotherapy.

MDA is very comparable to MDMA and is often described as a little more "trippy" and less euphoric than its cousin.

One method of MDA synthesis, is to turn safrole into isosafrole via isomerization. The isosafrole is then oxidized, using a Wacker process or a peroxyacid, to produce MDP2P (methylenedioxyphenylacetone). Finally, it is converted to MDA via reductive amination of Ammonia. This synthesis is very similar to that of Ecstasy and of MDEA.

MDA began to appear on the recreational drug scene around 1963 to 1964. It was then inexpensive and readily available as a research chemical from several scientific supply houses. Although now illegal, MDA continues to be bought, sold, and used for recreational purposes, often in the form of tablets purporting to contain MDMA (Ecstasy).

The MDA molecule
The MDA molecule

A recreational dose of MDA is commonly between 80 and 160mg. The “R” optical isomer is more potent than the “S” optical isomer. Although there is some debate, the duration of the drug is now generally believed to be roughly 6 to 10 hours(In the late 90s, Shulgin changed his opinion of the duration to 3-6 hours). The effects of the drug are quite similar to those of MDMA (Ecstasy), including empathogen/entactogenic effects, though typically less intense than a similar dosage of MDMA. Because of these effects, MDA was called the “hug drug” and was alleged to stand for “Mellow Drug of America” in the 1960s. Some users feel that MDA has more psychedelic or hallucinogenic qualities than MDMA.

The toxicity of MDA is not fully known. The LD50 in mice has been reported as 92mg/kg by intraperitoneal injection. Erowid lists the fatality rate at roughly 2 in 100,000 users. MDA is considered to be more potentially neurotoxic than its methylated cousin MDMA.[citation needed] It is a direct metabolite of MDMA.

In 1970, the Controlled Substances Act was enacted in the United States, placing MDA into Schedule I. It is similarly controlled in other nations. In Canada MDA is a Schedule III drug. Internationally, MDA is a Schedule I drug under the Convention on Psychotropic Substances[1].

  • Lee, M.A. and Shlain, B., Acid Dreams: The CIA, LSD, and the Sixties Rebellion. Grove, 1985.
  • Stafford, P. Psychedelics Encyclopedia. Ronin, 1992.

Advanced Search
Included Web Search Engines


Safe Search

close

Top Matching Results

Occasionally Search.com will highlight specialized results that are based on the context of your query. Examples of specialized results include specific links to news, images, or video.

Top Matching Results may highlight information from other Search.com pages, content from the CNET Network of sites, or third party content. The listings are based purely on relevance. Search.com does not receive payment for listings in this section but our partners that provide this data may get paid for listing these products.

Sponsored Links

This section contains paid listings which have been purchased by companies that want to have their sites appear for specific search terms and related content. These listings are administered, sorted and maintained by a third party and are not endorsed by Search.com.

Search Results

Search.com sends your search query to several search engines at one time and integrates the results into one list which has been sorted by relevance using Search.com's proprietary algorithm. You can customize the list of search engines included in your metasearch from the preferences.

The search engines that are used in your metasearch may allow companies to pay to have their Web sites included within the results. To view the Paid Inclusion policy for a specific search engine, please visit their Web site. Search.com does not accept payment or share revenue with any search engine partner for listings in this section.